Kabra Drugs

Is Kabra Drugs overvalued or undervalued?

As of November 12, 2024, Kabra Drugs is rated as risky and overvalued, with negative financial ratios compared to competitors like Sun Pharma and Cipla, despite a recent short-term stock performance that outpaced the Sensex.

As of 12 November 2024, the valuation grade for Kabra Drugs has moved from does not qualify to risky, indicating a significant shift in its financial standing. The company is currently assessed as overvalued, with a PE ratio of -27.57, an EV to EBITDA ratio of -28.95, and a ROCE of -33.00%. These negative ratios suggest that the company is facing substantial financial challenges compared to its peers.<BR><BR>In comparison to notable competitors, Kabra Drugs' valuation stands out unfavorably. For instance, Sun Pharma has a PE ratio of 35.25, while Cipla boasts a PE of 22.99, both indicating a much healthier valuation environment in the industry. The stark contrast in these ratios highlights the overvaluation of Kabra Drugs. Additionally, the company's recent stock performance has outpaced the Sensex over the past week, returning 4.99% compared to the Sensex's 1.45%, but this short-term gain does not mitigate the overall valuation concerns reflected in its financial ratios.

What is the technical trend for Kabra Drugs?

As of May 27, 2025, Kabra Drugs shows a mildly bullish trend, supported by positive MACD and RSI indicators, although caution is advised due to a mildly bearish KST on the weekly chart.

As of 27 May 2025, the technical trend for Kabra Drugs has changed from bullish to mildly bullish. The weekly MACD and RSI are both bullish, indicating positive momentum in the short term. The daily moving averages also reflect a bullish stance. However, the KST on a weekly basis is mildly bearish, suggesting some caution. The Bollinger Bands show a mildly bullish trend on the weekly chart while remaining bullish on the monthly chart. Dow Theory indicates no trend on the weekly but is mildly bullish on the monthly. Overall, the current technical stance is mildly bullish, driven primarily by the strong performance in MACD and RSI across multiple time frames.

Who are the peers of the Kabra Drugs?

Kabra Drugs' peers include Medi Caps, Shelter Pharma, Sandu Pharma, Transchem, Roopa Industries, Chandra Bhagat, ANG Lifesciences, JFL Life, and Medicamen Organ. Kabra Drugs leads with a 1-year return of 144.82%, while ANG Lifesciences has the lowest at -38.19%.

Peers: The peers of Kabra Drugs are Medi Caps, Shelter Pharma, Sandu Pharma, Transchem, Roopa Industries, Chandra Bhagat, ANG Lifesciences, JFL Life, and Medicamen Organ.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shelter Pharma, while Average management risk is found at Medi Caps and Transchem, and the rest have Below Average management risk. Growth is Good at Shelter Pharma and JFL Life, while Average growth is noted at Medi Caps and Roopa Industries, and the rest exhibit Below Average growth. Capital Structure is Excellent at Shelter Pharma, Good at Medi Caps and Sandu Pharma, while Average is seen at JFL Life, and the rest have Below Average capital structures.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kabra Drugs at 144.82%, while the peer with the lowest is ANG Lifesciences at -38.19%. Kabra Drugs' return significantly outperforms all peers. Additionally, Roopa Industries, Chandra Bhagat, ANG Lifesciences, and Shelter Pharma have negative six-month returns.

Who are in the management team of Kabra Drugs?

As of March 2021, the management team of Kabra Drugs includes B V Anatha Kumar (Whole Time Director & CFO), R Muralidharan, Ananthkumar Shilpa, Churchil Durai M Jebastine (all Independent Directors), Nidhi Bhaskar and Monika Sanwal (Company Secretaries), along with KUNIAMUTHUR NANJAPPAN ANAND and A Anitha (Additional Directors).

As of March 2021, the management team of Kabra Drugs includes the following individuals:<BR><BR>1. B V Anatha Kumar - Whole Time Director & CFO<BR>2. R Muralidharan - Independent Director<BR>3. Ananthkumar Shilpa - Independent Director<BR>4. Churchil Durai M Jebastine - Independent Director<BR>5. Nidhi Bhaskar - Company Secretary<BR>6. KUNIAMUTHUR NANJAPPAN ANAND - Additional Director<BR>7. Monika Sanwal - Company Secretary & Compliance Officer<BR>8. A Anitha - Additional Director<BR><BR>As of March 2021, the management team of Kabra Drugs comprises a mix of directors and officers, including a Whole Time Director, independent directors, and company secretaries.

What does Kabra Drugs do?

Kabra Drugs Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting a net profit of 4 Cr for March 2025, with a market cap of INR 48 Cr. Key metrics include a debt-equity ratio of -1.38 and a return on equity of 34%.

Overview: <BR>Kabra Drugs Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The specific year of incorporation is not provided, and there are no noted status changes. The latest quarter for which sales and profit are reported is March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 4 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 48 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -1.38 <BR>Return on Equity: 34.00% <BR>Price-to-Book: -45.90<BR><BR>Contact Details: <BR>Address: 270 Shastri Market Indore, Indore Madhya Pradesh: 452007 <BR>Email: kabradrugs@rediffmail.com <BR>Website: http://www.kabradrugslimited.com

Who are the top shareholders of the Kabra Drugs?

The top shareholders of Kabra Drugs are primarily individual investors, holding 96.19% of the shares, with Kuniamuthur Nanjappan Anand being the largest public shareholder at 6.53%. There are no institutional investors or pledged promoter holdings.

The top shareholders of Kabra Drugs primarily consist of individual investors, who hold a significant 96.19% of the company's shares. Among public shareholders, Kuniamuthur Nanjappan Anand stands out with a holding of 6.53%. There are no institutional investors or mutual funds currently holding shares in the company, and there are no pledged promoter holdings. Overall, the majority of the ownership is concentrated in the hands of individual investors.

How big is Kabra Drugs?

As of 24th July, Kabra Drugs Ltd has a market capitalization of 47.00 Cr, with reported Net Sales of 0.00 Cr and a Net Profit loss of 0.92 Cr for the latest four quarters. The company has Shareholder's Funds of 1.08 Cr and Total Assets of 4.57 Cr as of March 2024.

As of 24th July, Kabra Drugs Ltd has a market capitalization of 47.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Kabra Drugs reported Net Sales of 0.00 Cr and a Net Profit loss of 0.92 Cr.<BR><BR>For the latest annual period ending in March 2024, the company had Shareholder's Funds of 1.08 Cr and Total Assets of 4.57 Cr.

Are Kabra Drugs latest results good or bad?

Kabra Drugs' latest results show flat net sales but a significant 228.21% decline in standalone net profit, prompting MarketsMOJO to issue a 'Sell' recommendation. Investors should be cautious due to concerns about the company's profitability in a competitive market.

Kabra Drugs' latest results for the quarter ending June 2025 indicate a flat financial performance, with no significant changes in net sales compared to the previous quarter. However, the company has experienced a notable decline in standalone net profit, which dropped by 228.21% from the previous quarter, reflecting a challenging situation. <BR><BR>Given this performance, MarketsMOJO has issued a 'Sell' call on the stock, suggesting that investors should approach with caution. Overall, while the company shows stability in some metrics, the significant drop in profitability raises concerns about its current trajectory in the competitive pharmaceuticals and biotechnology sector. Investors will likely be looking for further developments in the upcoming quarters to better assess the company's future prospects.

Should I buy, sell or hold Kabra Drugs?

How has been the historical performance of Kabra Drugs?

Kabra Drugs has consistently generated no significant revenue from March 2021 to March 2025, with increasing operating losses reaching -1.08 Cr by March 2025, despite an improvement in shareholder's funds to 24.65 Cr due to increased equity capital. Total liabilities rose to 25.23 Cr, while financing activities resulted in a net cash inflow of 18.00 Cr.

Answer:<BR>The historical performance of Kabra Drugs shows a consistent lack of revenue generation, with net sales remaining at zero from March 2021 to March 2025, except for a nominal figure of 0.01 Cr in March 2019. The total operating income also reflects this trend, with minimal other operating income recorded in previous years. The company has incurred increasing total expenditures, rising from 0.05 Cr in March 2020 to 1.72 Cr in March 2025, primarily driven by employee costs and other expenses. Operating profit has been negative throughout this period, with losses deepening from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures mirror this decline, showing losses that have increased over the years. On the balance sheet, shareholder's funds improved from -0.73 Cr in March 2023 to 24.65 Cr in March 2025, largely due to an increase in equity capital. Total liabilities rose significantly to 25.23 Cr in March 2025, while total assets also increased to the same amount, indicating a growing but unprofitable operation. Cash flow from operating activities has been negative, with a notable cash inflow from financing activities in March 2025, resulting in a net cash inflow of 18.00 Cr.<BR><BR>Breakdown:<BR>Kabra Drugs has not generated any significant revenue over the years, with net sales consistently at zero from March 2021 to March 2025, except for a slight revenue in March 2019. The total operating income has remained low, with only minor other operating income recorded in earlier years. Total expenditures have escalated, particularly in employee costs and other expenses, leading to increasing operating losses, which reached -1.08 Cr by March 2025. The company's financial position has seen a notable improvement in shareholder's funds, which rose to 24.65 Cr in March 2025, driven by a substantial increase in equity capital. However, total liabilities also surged to 25.23 Cr, reflecting the company's growing financial obligations. Despite these challenges, cash flow from financing activities provided a significant boost, resulting in a net cash inflow of 18.00 Cr in March 2025, although cash flow from operating activities remained negative.

When is the next results date for Kabra Drugs Ltd?

The next results date for Kabra Drugs Ltd is 29 May 2026.

The next results date for Kabra Drugs Ltd is scheduled for 29 May 2026.

Why is Kabra Drugs Ltd falling/rising?

As of 02-Jun, Kabra Drugs Ltd's stock price is at 22.51, down 1.75% and reflecting a year-to-date decline of 26.32%. Despite a recent increase in investor participation, the stock remains below its moving averages, indicating a bearish trend amidst broader market declines.

As of 02-Jun, Kabra Drugs Ltd's stock price is currently at 22.51, reflecting a decrease of 0.4, or 1.75%. This decline is part of a broader trend, as the stock has experienced a significant drop of 26.32% year-to-date, compared to a 12.40% decline in the benchmark Sensex. Over the past week, the stock has fallen by 7.06%, while the Sensex has only decreased by 1.79%.<BR><BR>Despite today's performance showing a slight outperformance against its sector by 4.83% and a trend reversal after two consecutive days of decline, the stock remains below its moving averages across various time frames, indicating a bearish trend. Additionally, while there has been a notable increase in investor participation, with delivery volume rising by 156.78% on June 1st, the overall liquidity remains stable but does not counterbalance the ongoing downward pressure on the stock price. <BR><BR>In summary, the combination of a significant year-to-date decline, underperformance relative to moving averages, and the broader market context contributes to the current falling price of Kabra Drugs Ltd.

Which are the latest news on Kabra Drugs?